Antimicrobial stewardship approaches urgently need to be reinforced during the COVID-19 pandemic. This study evaluates the impact of the COVID-19 on antibiotic consumption
Description of the Study:
- Title: Antibiotic prescription during the COVID-19 pandemic: A biphasic pattern
- Principal investigator: Gabriela Abelenda Alonso, Ariadna Padullés, Alexander Rombauts, Carlota Gudiol, Miquel Pujol, Claudia Alvarez Pouso, Ramón Jodar and Jordi Carratalà.
- Centers of Implementation: Hospital Universitari de Bellvitge, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona and Spanish Network for Research in Infectious Diseases, Madrid.
- Study Population: Patients admitted in Hospital Universitari de Bellvitge from January 1 to April 30 in 2019 and 2020.
- Study Type: Before-and-after cross-sectional study.
- Design: Before-and-after cross-sectional study comparing data in 2019 (before the COVID-19 pandemic began) and 2020 (COVID-19) for the periods from January 1 to April 30.
- Methods: Medians for continuous variables were compared using the Wilcoxon log-rank test.
Objectives of the Study:
Principal Objective: To calculate the defined daily dose per 100 patient days, and based on the dispensing data of an electronic prescribing system.
More about this Study:
Scientific Context: The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a public health problem of historic dimensions. However, this pandemic is occurring in the setting of an antimicrobial resistance crisis that is increasing at an alarming pace worldwide.
Conclusions: Standardizing immunomodulatory treatments, ensuring compliance with usual infection control practices, and carefully interpreting microbiological results will be key measures that could favor a more cautious approach to the use of antibiotics.
In this study a biphasic pattern of increased antibiotic use was identified and that corresponded with a first wave of empirical antibiotic therapy and a second biphasic pattern with higher use of broad-spectrum antibiotics.
Data support the World Health Organization concern regarding inappropriate use of antibiotics during the pandemic and the recent change in its guidelines discouraging empirical antibiotics in COVID-19.
Hospital Universitari de Bellvitge: It is a 700-bed hospital that serves as a public referral center of 1 million inhabitants in Catalonia, the second worst pandemic-affected area in Spain. As of April 30, 2020, this hospital had had >1,293 hospital admissions for COVID-19, with a 317% increase in critical care bed use.
Other studies about Pharmacology:
Collaborez avec l’étude ANTICOV et contribuez à traiter la COVID-19 en Afrique.
Est-ce que les hormones sexuelles peuvent aider les hommes survivre le COVID-19 ? Cette étude a pour objectif évaluer la sécurité et l’efficacité de la progestérone dans le traitement de COVID-19 chez les hommes hospitalisés.
This study aims to demonstrate efficacy of Montelukast for patients with persistent COVID-19 to help them improve their quality of life.
CIBERES UCI COVID is a fundamental study that will improve care of critical patients infected by COVID-19.
This study aims to determine the effects of vaccination against SARS-CoV-2 in people with long COVID.
This study suggests that primary care diagnosis and treatment with antihistamines, plus azithromycin in selected cases, may treat COVID-19 and prevent progression to severe disease in elderly patients.
Clinical trial to perform immunomodulatory treatment in adult patients with severe COVID-19 pneumonia with the aim of helping to define the standard treatment for this disease.
This study aims to evaluate in clinical practice the efficacy and safety of remdesivir in patients admitted for COVID-19.
This multicentre clinical trial aims to demonstrate that treatment with Calcifediol reduces the need for invasive ventilation and Intensive Care Unit admissions and deaths.
Phase II clinical trial evaluating the safety and efficacy of the drug Maraviroc combined with standard therapy versus standard therapy in patients infected with SARS-CoV-2 and hospitalised with COVID-19.